Pardes Bioscience Announces Issuance of Its First U.S. Patent
September 21, 2021 16:05 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new...
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections
August 26, 2021 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the...
Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors
August 05, 2021 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat...